Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Norton Healthcare

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Indication: Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients with Relapsed or Refractory B-cell Non Hodgkin Lymphoma

Sub-indication: Hematological Malignancies

Study Type: Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Kymera Therapeutics, Inc

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Clinical Trial

Schedule an Appointment